University of Kentucky Medical Center, Lexington, KY 40536, USA.
J Vasc Surg. 2010 Mar;51(3):616-21, 621.e1-3. doi: 10.1016/j.jvs.2009.10.045. Epub 2010 Jan 27.
Little is known about the significance of blood transfusion in patients with peripheral arterial disease. We queried the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database to examine the effect of intraoperative blood transfusion on the morbidity and mortality in patients who underwent lower extremity revascularization.
We analyzed data from the participant use data file containing vascular surgical cases submitted to the ACS NSQIP in 2005, 2006, and 2007 by 173 hospitals. Current procedural terminology codes were used to select lower extremity procedures that were grouped into venous graft, prosthetic graft, or thromboendarterectomy. Thirty-day outcomes analyzed were (1) mortality, (2) composite morbidity, (3) graft/prosthesis failure, (4) return to the operating room within 30 days, (5) wound occurrences, (6) sepsis or septic shock, (7) pulmonary occurrences, and (8) renal insufficiency or failure. Intraoperative transfusion of packed red blood cells was categorized as none, 1 to 2 units, and 3 or more units. Outcome rates were compared between the transfused and nontransfused groups using the chi(2) test and multivariable regression adjusting for transfusion propensity, comorbid and procedural risk.
A total of 8799 patients underwent lower extremity revascularization between 2005 and 2007. Mean age was 66.8 +/- 12.0 years and 5569 (63.3%) were male. Transfusion rates ranged from 14.5% in thromboendarterectomy patients to 27.1% in prosthetic bypass patients (P < .05). After adjustment for transfusion propensity and patient and procedural risks, transfusion of 1 or 2 units remained significantly predictive of mortality, composite morbidity, sepsis/shock, pulmonary occurrences, and return to the operating room. The adjusted odds ratios for 30-day mortality ranged from 1.92 (95% confidence interval [CI] 1.36-2.70) for 1 to 2 units to 2.48 (95% CI 1.55-3.98) for 3 or more units.
In a large number of patients undergoing lower extremity revascularization, we have found that there is a higher risk of postoperative mortality, pulmonary, and infectious complications after receiving intraoperative blood transfusion. Additional studies are necessary to better define transfusion triggers that balance the risk/benefit ratio for blood transfusion.
关于外周动脉疾病患者输血的意义知之甚少。我们查询了美国外科医师学会国家外科质量改进计划(ACS NSQIP)数据库,以研究术中输血对下肢血运重建患者发病率和死亡率的影响。
我们分析了参与者使用数据文件中的数据,该数据文件包含 2005 年、2006 年和 2007 年 173 家医院提交给 ACS NSQIP 的血管外科病例。使用当前的程序术语代码选择下肢手术,将其分为静脉移植物、假体移植物或血栓内膜切除术。分析的 30 天结果包括:(1)死亡率,(2)复合发病率,(3)移植物/假体失败,(4)30 天内返回手术室,(5)伤口事件,(6)败血症或感染性休克,(7)肺部事件,和(8)肾功能不全或衰竭。术中输注红细胞被分为无、1-2 单位和 3 个或更多单位。使用卡方检验和多变量回归比较输血组和非输血组之间的结果率,同时调整输血倾向、合并症和手术风险。
2005 年至 2007 年期间,共有 8799 例患者接受了下肢血运重建。平均年龄为 66.8±12.0 岁,5569 例(63.3%)为男性。输血率从血栓内膜切除术患者的 14.5%到假体旁路患者的 27.1%(P<.05)。调整输血倾向和患者及手术风险后,输注 1 或 2 单位仍显著预测死亡率、复合发病率、败血症/休克、肺部事件和返回手术室。30 天死亡率的调整比值比范围为 1 至 2 单位的 1.92(95%置信区间[CI] 1.36-2.70)至 3 个或更多单位的 2.48(95%CI 1.55-3.98)。
在大量接受下肢血运重建的患者中,我们发现接受术中输血后,术后死亡率、肺部和感染性并发症的风险更高。需要进一步研究以更好地确定输血触发因素,平衡输血的风险/效益比。